Filing Summary: Parnes Harold S Just Disclosed New Boston Therapeutics, Inc Position

Filing Summary: Parnes Harold S Just Disclosed New Boston Therapeutics, Inc Position

The New Parnes Harold S Holding in Boston Therapeutics, Inc

Parnes Harold S filed with the SEC SC 13D/A form for Boston Therapeutics, Inc. The form can be accessed here: 000161577416007615. As reported in Parnes Harold S’s form, the filler as of late owns 9.92% or 4,398,000 shares of the -company.

Boston Therapeutics, Inc stake is a new one for the and it was filed because of activity on August 12, 2016. We feel this shows Parnes Harold S’s positive view for the stock.

Reasons Why Parnes Harold S Bought – Boston Therapeutics, Inc Stock

Item4. Purpose of Transaction

The Reporting Person has acquired the Securitiesof the Issuer for investment purposes, and such purchases have been made in the Reporting Person’s ordinary course of business.

Business Profile

Boston Therapeutics, Inc. (BTI) is a pre-clinical and clinical-stage pharmaceutical company. The Company is focused on the development, manufacture and commercialization of carbohydrate-based therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. BTI-320 is its lead product candidate. BTI-320 is a Carbohydrate hydrolyzing Enzyme Inhibitor for treatment of patients with Type 2 diabetes. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications, which is designed to reduce post-meal glucose elevation. BTI-320 is in Phase II clinical development. IPOXYN and OXYFEX are in pre-clinical stage of drug development. IPOXYN is indicated for lower limb vascular complications of diabetes. OXYFEX is indicated for veterinary ischemic tissue. It produces and sells SUGARDOWN, a non-systemic carbohydrate-based dietary food supplement to support post-meal blood glucose.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Analysts await Boston Therapeutics Inc (OTCMKTS:BTHE) to report earnings on November, 18.

The stock decreased 3.03% or $0.005 on October 13, hitting $0.16. About 117 shares traded hands. Boston Therapeutics Inc (OTCMKTS:BTHE) has risen 41.67% since March 10, 2016 and is uptrending. It has outperformed by 34.15% the S&P500.

Boston Therapeutics, Inc. is a pre-clinical and clinical-stage pharmaceutical company. The company has a market cap of $7.17 million. The Firm is focused on the development, manufacture and commercialization of carbohydrate therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. It currently has negative earnings. BTI-320 is its lead product candidate.

More notable recent Boston Therapeutics Inc (OTCMKTS:BTHE) news were published by: Marketwatch.com which released: “Boston Therapeutics Completes Private Offering, Appoints New CEO” on October 03, 2016, also Marketwired.com with their article: “Boston Therapeutics Reports Positive Topline Data From Proof of Concept Asia Trial” published on October 06, 2016, Bostonglobe.com published: “Relay Therapeutics lands $57m to make movies of cell proteins” on September 14, 2016. More interesting news about Boston Therapeutics Inc (OTCMKTS:BTHE) were released by: Bostonglobe.com and their article: “Intarcia kicks off new funding that could bring $4b valuation” published on September 15, 2016 as well as Businesswire.com‘s news article titled: “vTv Therapeutics to Present at Neuro Advance Boston” with publication date: October 03, 2016.

According to Zacks Investment Research, “Boston Therapeutics, Inc. is a pharmaceutical company engaged in the development, manufacturing, and commercialization of compounds for the treatment of diabetes and inflammatory diseases. The Company focuses on glyco-pathology. Its product portfolio includes SUGARDOWN(R), PAZ320 and IPOXYN(TM). Boston Therapeutics, Inc. is based in Manchester, New Hampshire.”

BTHE Company Profile

Boston Therapeutics, Inc. (BTI), incorporated on August 24, 2009, is a pre-clinical and clinical-stage pharmaceutical company. The Firm is focused on the development, manufacture and commercialization of carbohydrate therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. The Company’s product candidates include BTI-320, IPOXYN and OXYFEX, and SUGARDOWN.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment